BIOTECHNOLOGY VALUE FUND L P
CIK 918923 · last filed 2026-04-02
BIOTECHNOLOGY VALUE FUND L P is a corporate insider who has filed 47 SEC Form 4 insider transactions across 22 companies since 2008. The most recent filing shows the insider sold $629.6M of MLTX on Apr 2, 2026. Across all open-market trades the lifetime net is −$1.54B, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.34B across reported positions. The firm reports its address in San Francisco, CA. 513 SEC filings were submitted jointly with BVF INC/IL.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.34B
22
47
-$1.54B
Filer Profile
40TH FL
SAN FRANCISCO, CA 94104
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MLTX | Director | 8,302,735 | $12.51 | $103.87M | -$1.63B | 2 | 2026-04-02 |
| OLMA | Director | 2,990,983 | $10.22 | $30.57M | $0 | 1 | 2024-12-04 |
| Third Harmonic Bio, Inc. (THRD) Delisted | 1,794,218 | $5.38 | $9.65M | -$143.00M | 1 | 2024-10-31 | |
| KYMR | Director | 294,632 | $114.96 | $33.87M | $1.41M | 3 | 2024-06-28 |
| Repare Therapeutics Inc. (RPTX) Delisted | 10%+ Owner | 548,938 | $2.65 | $1.45M | $203.21M | 2 | 2023-11-17 |
| RAIN | 1,076,314 | $0.74 | $795.4K | $99.26M | 2 | 2021-09-15 | |
| XOMA Royalty Corp (XOMAP) Delisted | 10%+ Owner | 1,960,384 | $24.98 | $48.97M | -$249.99M | 1 | 2021-04-02 |
| Merus N.V. (MRUS) Delisted | 427,377 | $90.00 | $38.46M | $57.50M | 1 | 2021-03-18 | |
| XOMA Royalty Corp (XOMA) Delisted | 10%+ Owner | 171,336 | $40.17 | $6.88M | $15.59M | 3 | 2020-09-23 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | 10%+ Owner | 3,078,989 | $38.00 | $117.00M | $14.60M | 1 | 2019-12-26 |
| CYTK | 2,811,818 | $73.77 | $207.43M | $22.60M | 1 | 2019-12-12 | |
| Calithera Biosciences, Inc. (CALA) Delisted | 32,371 | $0.00 | $10 | $44.17M | 1 | 2019-10-31 | |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | 10%+ Owner | 1,167,191 | $0.04 | $52.2K | $47.24M | 3 | 2018-06-21 |
| XENE | 297,464 | $58.65 | $17.45M | $4.07M | 3 | 2017-08-16 | |
| PTN | 122,877 | $11.80 | $1.45M | -$2.14M | 1 | 2014-02-19 | |
| LGND | 3,299,569 | $284.47 | $938.63M | $6.20M | 8 | 2012-12-18 | |
| CAPS | 1,322 | $0.18 | $240 | $338.5K | 2 | 2011-07-28 | |
| FACT | 7,849,140 | $10.72 | $84.14M | $3.64M | 1 | 2010-02-09 | |
| EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | 16,062,944 | — | — | -$10.89M | 2 | 2009-12-24 | |
| DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | 1,098,392 | $15.50 | $17.03M | -$21.87M | 2 | 2009-08-10 | |
| NBIX | 5,905,447 | $156.22 | $922.55M | $1.80M | 3 | 2009-01-22 | |
| AVIGEN INC \DE (AVGN) Delisted | 8,279,715 | — | — | $584.3K | 1 | 2008-11-20 |
Recent Filings
47 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-04-02 | MLTX | Sell (S) | −37,500,000 | -$629.62M | EDGAR |
| 2024-12-04 | OLMA | Mixed | −33,697,040 | $0 | EDGAR |
| 2024-10-31 | Third Harmonic Bio, Inc. (THRD) Delisted | Sell (S) | −10,000,000 | -$143.00M | EDGAR |
| 2024-10-08 | MLTX | Sell (S) | −20,000,000 | -$1.00B | EDGAR |
| 2024-06-28 | KYMR | Grant (A) | — | $0 | EDGAR |
| 2023-11-17 | Repare Therapeutics Inc. (RPTX) Delisted | Buy (P) | +12,273,010 | $62.50M | EDGAR |
| 2022-06-17 | KYMR | Grant (A) | — | $0 | EDGAR |
| 2022-05-24 | KYMR | Buy (P) | +101,000 | $1.41M | EDGAR |
| 2022-01-21 | Repare Therapeutics Inc. (RPTX) Delisted | Buy (P) | +9,979,610 | $140.71M | EDGAR |
| 2021-09-15 | RAIN | Buy (P) | +3,922,690 | $64.69M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.